Congenital Adrenal Hyperplasia clinical trials

Explore recruiting congenital adrenal hyperplasia clinical trials.

Recruiting congenital adrenal hyperplasia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Congenital Adrenal Hyperplasia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia

Sweden, Netherlands, Ireland, Italy, Romania, Estonia +6 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia

Sweden, Netherlands, Denmark, Romania, Ireland, Latvia +6 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants with Congenital Adrenal Hyperplasia Including a Long-Term Extension

Italy, Germany, France, Belgium, Netherlands, Poland

Phase II and Phase III (Integrated) EU CTIS Study details

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants with Classic Congenital Adrenal Hyperplasia

Sweden, Austria, Poland, Netherlands, Italy, France +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A 12-Week, Phase 2 Open-Label, Sequential Dose Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 Treatment in Participants with Congenital Adrenal Hyperplasia

Germany, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-label, Long-term Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants with Congenital Adrenal Hyperplasia

Italy, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Congenital Adrenal Hyperplasia trials by city

Congenital Adrenal Hyperplasia in Toronto Congenital Adrenal Hyperplasia in Vancouver Congenital Adrenal Hyperplasia in Montreal Congenital Adrenal Hyperplasia in Calgary Congenital Adrenal Hyperplasia in Edmonton Congenital Adrenal Hyperplasia in Ottawa Congenital Adrenal Hyperplasia in Winnipeg Congenital Adrenal Hyperplasia in Quebec City Congenital Adrenal Hyperplasia in Hamilton Congenital Adrenal Hyperplasia in Kitchener Congenital Adrenal Hyperplasia in London Congenital Adrenal Hyperplasia in Halifax Congenital Adrenal Hyperplasia in New York Congenital Adrenal Hyperplasia in Los Angeles Congenital Adrenal Hyperplasia in Chicago Congenital Adrenal Hyperplasia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease